Meeting - London, United Kingdom
The SMR are pleased to announce that the 2014 SMR Award for Drug Discovery, is to be awarded to Pharmacyclics for the discovery and development of Ibrutinib (ImbruvicaTM), a first in human BTK covalent inhibitor for the treatment of a number of B-cell malignancies.The award will be presented during the the December 2014 SMR meeting “Recent Disclosures of Clinical Candidates”.
Together with the SMR award lecture the “Recent Disclosures of Clinical Candidates” meeting features an excellent array of novel molecular therapeutics across several target classes and therapeutic areas, which include oncology (inhibitors of BTK and Mdm2), pain (Nav1.7 modulation), CNS (highly selective M1 agonists and BACE1 inhibitors), bacterial infection (inhibitors of Clostridium difficile) and allergic inflammation (intranasal TLR7 agonists).
- Organization: Society of Medicines Research
Thu, Dec 04, 2014 - Thu, Dec 04, 2014
National Heart and Lung Institute Faculty of medicine
Dovehouse St, South Kensington, London SW3 6LY, United Kingdom
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.
